Uniphar plc (LON:UPR - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 314 ($4.28) and last traded at GBX 310 ($4.22), with a volume of 11207 shares traded. The stock had previously closed at GBX 307 ($4.18).
Wall Street Analyst Weigh In
Separately, Shore Capital reiterated a "buy" rating on shares of Uniphar in a research report on Thursday, May 29th.
Check Out Our Latest Report on Uniphar
Uniphar Stock Performance
The stock's 50 day moving average is GBX 267.08 and its two-hundred day moving average is GBX 220.29. The stock has a market capitalization of £1.02 billion, a price-to-earnings ratio of 22.70 and a beta of 0.75. The company has a current ratio of 0.90, a quick ratio of 0.60 and a debt-to-equity ratio of 119.48.
About Uniphar
(
Get Free Report)
Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.
Featured Articles
Before you consider Uniphar, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Uniphar wasn't on the list.
While Uniphar currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
